Background: Somnolence and sedation are common treatment-emergent adverse events (TEAEs) reported with current antipsychotics. Lumateperone (lumateperone tosylate, ITI-007), a mechanistic...
Background: Treatments for bipolar depression are limited. Lumateperone (lumateperone tosylate, ITI-007), a mechanistically novel antipsychotic that simultaneously modulates serotonin, do...
Background: Antipsychotic treatment of schizophrenia is often associated with increased rates of metabolic syndrome (MetSy), as defined by criteria for waist circumference, triglycerides,...
Introduction: Lumateperone (lumateperone tosylate, ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that simultaneously modu...
Introduction: Lumateperone (ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that modulates serotonin, dopamine, and glutama...
Introduction: Lumateperone (ITI-007) is in development for the treatment of schizophrenia and bipolar depression. Lumateperone has a unique mechanism of action that simultaneously modulat...
Introduction: Patients with schizophrenia are a heterogenous population and understanding which factors may influence antipsychotic efficacy is important in improving outcomes. Lumatepero...
Background: Lumateperone is a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems.